Literature DB >> 28593553

Prenatal diagnosis of spina bifida: from intracranial translucency to intrauterine surgery.

Waldo Sepulveda1, Amy E Wong2, Francisco Sepulveda3, Juan L Alcalde4, Juan C Devoto5, Felipe Otayza6.   

Abstract

Accurate and timely prenatal diagnosis of spina bifida (SB) is a major goal of modern antenatal care. Prenatal screening for open SB should be first performed at the time of routine first-trimester ultrasound by examining the posterior fossa for obliteration or non-visualization of the fourth ventricle ("intracranial translucency") and cisterna magna. The second step of screening is the second-trimester anatomy scan, at which time the features of the Chiari type II malformation should be looked for, including ventriculomegaly, scalloping of the frontal bones ("lemon" sign), and backward and caudal displacement of the cerebellar vermis with obliteration of the cisterna magna ("banana" sign). In cases with positive findings, evaluation must include a focused examination of the spine for defects. In cases of closed SB and SB occulta, the cranial and posterior fossa features will not be present as they are not associated with leaking of spinal fluid and resultant hindbrain herniation, highlighting the fact that the spine should be examined thoroughly whenever possible during the second-trimester scan. In tertiary fetal medicine centers, two-dimensional and three-dimensional ultrasound allows an accurate determination of the location, type, extent, and upper level of the spinal defect as well as the presence of associated anomalies. Fetal magnetic resonance imaging should be restricted to candidates for intrauterine surgery as part of the preoperative protocol.

Entities:  

Keywords:  Fetal anomalies; Fetal magnetic resonance imaging; Fetal ultrasound; Myelomeningocele; Open neural tube defects; Prenatal diagnosis; Spina bifida; Three-dimensional ultrasound

Mesh:

Year:  2017        PMID: 28593553     DOI: 10.1007/s00381-017-3445-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  116 in total

1.  Cranial and cerebral signs in the diagnosis of spina bifida between 18 and 22 weeks of gestation: a German multicentre study.

Authors:  F Bahlmann; I Reinhard; T Schramm; A Geipel; U Gembruch; C S von Kaisenberg; R Schmitz; J Stupin; R Chaoui; K Karl; K Kalache; F Faschingbauer; M Ponnath; A Rempen; P Kozlowski
Journal:  Prenat Diagn       Date:  2015-02-04       Impact factor: 3.050

2.  Fluid area measurements in the posterior fossa at 11-13 weeks in normal fetuses and fetuses with open spina bifida.

Authors:  Katrin Karl; Kai Sven Heling; Rabih Chaoui
Journal:  Fetal Diagn Ther       Date:  2015-02-10       Impact factor: 2.587

3.  Screening for fetal spina bifida at the 11-13-week scan using three anatomical features of the posterior brain.

Authors:  R Mangione; F Dhombres; N Lelong; S Amat; F Atoub; S Friszer; B Khoshnood; J-M Jouannic
Journal:  Ultrasound Obstet Gynecol       Date:  2013-10       Impact factor: 7.299

4.  Ultrasound screening for spina bifida: cranial and cerebellar signs in a high-risk population.

Authors:  J Campbell; W M Gilbert; K H Nicolaides; S Campbell
Journal:  Obstet Gynecol       Date:  1987-08       Impact factor: 7.661

5.  Amniotic-fluid alpha-fetoprotein in the antenatal diagnosis of spina bifida.

Authors:  L D Allan; M A Ferguson-Smith; I Donald; E M Sweet; A A Gibson
Journal:  Lancet       Date:  1973-09-08       Impact factor: 79.321

6.  A randomized trial of prenatal versus postnatal repair of myelomeningocele.

Authors:  N Scott Adzick; Elizabeth A Thom; Catherine Y Spong; John W Brock; Pamela K Burrows; Mark P Johnson; Lori J Howell; Jody A Farrell; Mary E Dabrowiak; Leslie N Sutton; Nalin Gupta; Noel B Tulipan; Mary E D'Alton; Diana L Farmer
Journal:  N Engl J Med       Date:  2011-02-09       Impact factor: 91.245

7.  Is MSAFP still a useful test for detecting open neural tube defects and ventral wall defects in the era of first-trimester and early second-trimester fetal anatomical ultrasounds?

Authors:  Ashley S Roman; Simi Gupta; Nathan S Fox; Daniel Saltzman; Chad K Klauser; Andrei Rebarber
Journal:  Fetal Diagn Ther       Date:  2014-07-12       Impact factor: 2.587

8.  Computed tomographic signs of the Chiari II malformation. Part I: Skull and dural partitions.

Authors:  T P Naidich; R M Pudlowski; J B Naidich; M Gornish; F J Rodriguez
Journal:  Radiology       Date:  1980-01       Impact factor: 11.105

Review 9.  Global Birth Prevalence of Spina Bifida by Folic Acid Fortification Status: A Systematic Review and Meta-Analysis.

Authors:  Callie A M Atta; Kirsten M Fiest; Alexandra D Frolkis; Nathalie Jette; Tamara Pringsheim; Christine St Germaine-Smith; Thilinie Rajapakse; Gilaad G Kaplan; Amy Metcalfe
Journal:  Am J Public Health       Date:  2015-11-12       Impact factor: 9.308

10.  Are routine alpha-fetoprotein and acetylcholinesterase determinations still necessary at second-trimester amniocentesis? Impact of high-resolution ultrasonography.

Authors:  W Sepulveda; A Donaldson; R D Johnson; G Davies; N M Fisk
Journal:  Obstet Gynecol       Date:  1995-01       Impact factor: 7.661

View more
  4 in total

Review 1.  Spina bifida in pregnancy: A review of the evidence for preconception, antenatal, intrapartum and postpartum care.

Authors:  Kenga Sivarajah; Sophie Relph; Radha Sabaratnam; Spyros Bakalis
Journal:  Obstet Med       Date:  2018-05-17

2.  Pediatric Spina Bifida and Spinal Cord Injury.

Authors:  Joslyn Gober; Sruthi P Thomas; David R Gater
Journal:  J Pers Med       Date:  2022-06-17

3.  Qualitative and quantitative study of fetal posterior fossa during the first trimester in a Chinese population.

Authors:  Li Feng; Lijuan Sun; Jingjing Wang; Congxin Sun; Lijuan Lu; Zhikun Zhang; Yu Hu; Qingqing Wu
Journal:  BMC Pregnancy Childbirth       Date:  2022-10-10       Impact factor: 3.105

4.  Fetal profile in fetuses with open spina bifida.

Authors:  Natalia Prodan; Markus Hoopmann; Jiri Sonek; Christoph Oettling; Harald Abele; Philipp Wagner; Karl Oliver Kagan
Journal:  Arch Gynecol Obstet       Date:  2020-03-24       Impact factor: 2.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.